Insider Selling: Q32 Bio (NASDAQ:QTTB) CFO Sells 3,995 Shares of Stock

Q32 Bio Inc. (NASDAQ:QTTB) CFO Lee Kalowski sold 3,995 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total transaction of $18,017.45. Following the completion of the transaction, the chief financial officer directly owned 35,943 shares in the company, valued at approximately $162,102.93. The trade was a 10.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Lee Kalowski also recently made the following trade(s):

• On Tuesday, December 2nd, Lee Kalowski sold 9,072 shares of Q32 Bio stock. The stock was sold at an average price of $3.46, for a total transaction of $31,389.12.

Q32 Bio Price Performance

Shares of QTTB stock traded down $0.20 during trading hours on Friday, reaching $4.56. The company had a trading volume of 203,990 shares, compared to its average volume of 164,705. Q32 Bio Inc. has a 1-year low of $1.35 and a 1-year high of $6.37. The firm has a market cap of $56.09 million, a price-to-earnings ratio of -1.33 and a beta of 0.16. The company has a 50 day moving average of $3.78 and a 200 day moving average of $2.88.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on QTTB. Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a research report on Friday, January 9th. HC Wainwright assumed coverage on shares of Q32 Bio in a report on Wednesday. They set a “buy” rating and a $13.00 price objective for the company. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $14.00.

Key Headlines Impacting Q32 Bio

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Hedge Funds Weigh In On Q32 Bio

Several institutional investors and hedge funds have recently modified their holdings of QTTB. XTX Topco Ltd acquired a new stake in Q32 Bio during the 4th quarter worth approximately $68,000. Opaleye Management Inc. bought a new stake in shares of Q32 Bio during the fourth quarter worth $708,000. ADAR1 Capital Management LLC acquired a new stake in shares of Q32 Bio during the fourth quarter worth $66,000. Jane Street Group LLC acquired a new stake in shares of Q32 Bio during the fourth quarter worth $84,000. Finally, HRT Financial LP lifted its position in Q32 Bio by 66.5% in the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after acquiring an additional 9,862 shares in the last quarter. 31.32% of the stock is currently owned by institutional investors and hedge funds.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.